Stocklytics Platform
Asset logo for symbol CYTK
Cytokinetics
CYTK
60
$51.94arrow_drop_down1.59%-$0.84
High Growth

Performance History

Chart placeholder
Key Stats
Open$52.71
Prev. Close$52.78
EPS-5.4
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$6.08B
PE Ratio-
LOWHIGH
Day Range51.57
53.44
52 Week Range25.98
110.25
Ratios
P/B Ratio31.90
Revenue$7.53M
Operating M. %-15,117.96%
Earnings$0.00
Earnings Growth %-35.30%
EBITDA Margin %-1,000.00%
ROE %-572.15%
EPS-5.4

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$891.46
Perf. (24h)
arrow_drop_up0.72%$6.45
Market Cap$834.88B
Price$481.04
Perf. (24h)
0.00%$0.00
Market Cap$451.06B
Price$145.64
Perf. (24h)
arrow_drop_down0.20%-$0.30
Market Cap$350.26B
Price$127.99
Perf. (24h)
arrow_drop_up0.38%$0.49
Market Cap$327.94B

About Cytokinetics (CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert I. Blum
Headquarters
South San Francisco
Employees
409
Exchange
NASDAQ
add Cytokinetics  to watchlist

Keep an eye on Cytokinetics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Cytokinetics 's (CYTK) price per share?

The current price per share for Cytokinetics (CYTK) is $51.94. The stock has seen a price change of -$0.84 recently, indicating a -1.59% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Cytokinetics (CYTK)?

For Cytokinetics (CYTK), the 52-week high is $110.25, which is 112.26% from the current price. The 52-week low is $25.98, the current price is 99.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Cytokinetics (CYTK) a growth stock?

Cytokinetics (CYTK) has shown an average price growth of 0.41% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cytokinetics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Cytokinetics (CYTK) stock price performance year to date (YTD)?

As of the latest data, Cytokinetics (CYTK) has a year-to-date price change of -38.25%. Over the past month, the stock has experienced a price change of -14.29%. Over the last three months, the change has been -18.53%. Over the past six months, the figure is 43.92%. Looking at a longer horizon, the five-year price change stands at 370.47%.

help
Is Cytokinetics (CYTK) a profitable company?

Cytokinetics (CYTK) has a net income of -$526.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -15.12K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $7.53M, although specific revenue growth data is currently not available. Operating income is noted at -$496.2M. Furthermore, the EBITDA is -$485.59M.

help
What is the market capitalization of Cytokinetics (CYTK)?

Cytokinetics (CYTK) has a market capitalization of $6.09B. The average daily trading volume is 1.69M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level